Targeting deadly lung-scarring disease, Peninsula biotech snares $100M crossover round
March 03, 2020 at 09:24 AM EST
The new funding has set the table for the South San Francisco biotech to serve up an IPO.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|